CAMBRIDGE, Mass., Feb. 12,
2024 /PRNewswire/ -- NeuroBo Pharmaceuticals,
Inc. (Nasdaq: NRBO), a clinical-stage biotechnology
company focused on transforming cardiometabolic diseases, today
announced that Hyung Heon Kim,
President and Chief Executive Officer and Marshall H. Woodworth, Acting Chief Financial
Officer, will participate in one-on-ones with investors and
business development meetings with biopharmaceutical executives at
the BIO CEO & Investor Conference, taking place February 26-27, 2024 in New York.
Interested parties can request a meeting through the BIO
One-on-One Partnering System™:
https://partnering.bio.org/ceo2024
To schedule a meeting with management outside of the conference,
please contact Michael Miller at
mmiller@rxir.com.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology
company focused on transforming cardiometabolic diseases. The
company is currently developing DA-1241 for the treatment of
Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2
Diabetes Mellitus (T2DM), and is developing DA-1726 for the
treatment of obesity. DA-1241 is a novel G-protein-coupled receptor
119 (GPR119) agonist that promotes the release of key gut peptides
GLP-1, GIP, and PYY. In preclinical studies, DA-1241 demonstrated a
positive effect on liver inflammation, lipid metabolism, weight
loss, and glucose metabolism, reducing hepatic steatosis, hepatic
inflammation, and liver fibrosis, while also improving glucose
control. DA-1726 is a novel oxyntomodulin (OXM) analogue that
functions as a glucagon-like peptide-1 receptor (GLP1R) and
glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring
gut hormone that activates GLP1R and GCGR, thereby decreasing food
intake while increasing energy expenditure, thus potentially
resulting in superior body weight loss compared to selective GLP1R
agonists.
For more information, please visit www.neurobopharma.com.
Contact:
NeuroBo Pharmaceuticals
Marshall H. Woodworth
Interim Chief Financial Officer
+1-857-299-1033
marshall.woodworth@neurobopharma.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-to-participate-in-the-bio-ceo--investor-conference-302058649.html
SOURCE NeuroBo Pharmaceuticals, Inc.